Efficacy of combined VEGFR1-3, PDGF α/β, and FGFR1-3 blockade using nintedanib for esophagogastric cancer.

CONCLUSIONS: Nintedanib treatment resulted in modest disease stabilization in patients with metastatic esophagogastric cancer. Alterations in cell cycle pathway genes and increased global copy-number alteration burden warrant further study as prognostic or predictive biomarkers.
PMID: 30952642 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - April 4, 2019 Category: Cancer & Oncology Authors: Won E, Basunia A, Chatila WK, Hechtman JF, Chou JF, Ku GY, Chalasani SB, Boyar MS, Goldberg Z, Desai AM, Tuvy Y, Berger MF, Tang LH, Kelsen DP, Schattner M, Ilson DH, Capanu M, Solit DB, Schultz N, Janjigian YY Tags: Clin Cancer Res Source Type: research